RankAlpha logo
Back to Rankings

MRNA

ModernaF
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
+
Peers tracked
11
U.S. public peers
Grade Position
Below peers
vs peer average
MRNA vs peer average
22/100
MRNA vs. peer average (F vs. C)
Grade spread
A 2 · B 3 · C 1 · F 5
Graded peers loaded
Coverage
11 graded
100% of tracked

Peer overview

ASND is the first available peer comparator.

Ascendis is a closer market-cap biopharma comp with a rare-disease commercialization and pipeline-conversion story, highlighting that Moderna still needs cleaner proof that new launches can diversify revenue beyond COVID.

✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
Top peerASNDAscendis A/S
MRNA
Moderna
ASND
Ascendis A/S
Grade
F
F
Momentum
100
42
Value
41
58
Sentiment
0
0
Setup Bias
Net —
-
Market Cap
-
-
Posture
Defensive
Defensive
Open Side-by-Side ComparisonCompare all

Grade position vs ASND

MRNA / ASND
Grade Position
Below peers
MRNA vs. peer average (F vs. C)
22/100
Momentum
100
MRNA
Value
41
ASND
Sentiment
0
MRNA

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank
Ticker
Company
Grade
Grade score
vs MRNA
1
ASND
ASND
F
20/100
Even
2
IONS
IONS
A
100/100
-4
3
MDGL
MDGL
F
20/100
Even
4
ROIV
Roivant Sciences Ltd Common
F
20/100
Even
5
INCY
Incyte Corp Common
B
80/100
-3
ASND is the first peer returned for this comparison set.